scholarly journals Percutaneous Edge-to-Edge Mitral Valve Repair in High-Surgical-Risk Patients

2012 ◽  
Vol 5 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Ben J.L. Van den Branden ◽  
Martin J. Swaans ◽  
Martijn C. Post ◽  
Benno J.W.M. Rensing ◽  
Frank D. Eefting ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Valve Repair ◽  
Surgical Risk ◽  
High Surgical Risk ◽  
Risk Patients

Long-term survival and preprocedural predictors of mortality in high surgical risk patients undergoing percutaneous mitral valve repair

2015 ◽  
Vol 87 (3) ◽  
pp. 467-475 ◽  
Author(s):  
Andreas S. Triantafyllis ◽  
Friso Kortlandt ◽  
Annelies L.M. Bakker ◽  
Martin J. Swaans ◽  
Frank D. Eefting ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Repair ◽  
Valve Repair ◽  
Term Survival ◽  
Surgical Risk ◽  
Long Term Survival ◽  
Percutaneous Mitral Valve Repair ◽  
High Surgical Risk ◽  
Risk Patients

scholarly journals Survival of Transcatheter Mitral Valve Repair Compared With Surgical and Conservative Treatment in High-Surgical-Risk Patients

2014 ◽  
Vol 7 (8) ◽  
pp. 875-881 ◽  
Author(s):  
Martin J. Swaans ◽  
Annelies L.M. Bakker ◽  
Arash Alipour ◽  
Martijn C. Post ◽  
Johannes C. Kelder ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Conservative Treatment ◽  
Mitral Valve Repair ◽  
Valve Repair ◽  
Surgical Risk ◽  
Transcatheter Mitral Valve Repair ◽  
High Surgical Risk ◽  
Risk Patients

scholarly journals Residual mitral regurgitation impact on outcomes after mitraclip therapy: five-year follow-up from the GRASP registry

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
AM Caggegi ◽  
P Capranzano ◽  
S Scandura ◽  
S Mangiafico ◽  
G Castania ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Primary Endpoint ◽  
Left Ventricular ◽  
Valve Repair ◽  
Surgical Risk ◽  
High Surgical Risk ◽  
Mitraclip Therapy

Abstract Funding Acknowledgements Type of funding sources: None. Background – Although percutaneous mitral valve repair is an attractive alternative treatment option for patients with severe mitral regurgitation (MR) at high surgical risk, residual MR is commonly observed after the procedure and little is known about its impact on outcomes after MitraClip therapy, expecially in patients with severe left ventricular (LV) impairment. Purpose – The aim of this prospective, observational study was to evaluate the impact of residual MR (MR ≤1+ vs. MR >1+) on long-term outcomes of mitral valve repair with the MitraClip System in high surgical risk patients presenting with moderate-to-severe or severe MR and with severe reduction of LV ejection fraction (EF). Methods – Patients enrolled in the prospective Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) with functional MR and EF ≤30% who were eligible at almost five-year follow-up were included in the present analysis.  The primary endpoint was death at 5-year follow-up.  Also echocardiographic parameters at baseline and 5-year follow-up and rehospitalization rates were assessed. Results – A total of 139 patients were included: 92 (66.2%) with post-procedural residual MR ≤1+ and 47 (33.8%) with residual MR > 1+ (41 patients with residual MR 2+, 5 with residual MR 3+, 1 with residual MR 4+).  Comparable clinical and echocardiographic baseline characteristics were observed between the two groups except for NYHA functional class IV and implanted pace-maker (more frequent in patients with residual MR >1+) and previous myocardial infarction (more frequent  in patients with residual MR ≤1+). At 5-year follow-up, no significant differences were reported in the primary endpoint (49.6% in patients with residual MR ≤ 1+ vs. 65.3% in patients with residual MR > 1+, p 0.203) and in cardiac death (37.8% in patients with residual MR ≤ 1+ vs. 42.6% in patients with residual MR > 1+, p 0.921). Cox regression analysis identified residual MR > 1+ as an independent predictor of re-hospitalization (HR 0.51, 95% CI 0.28-0.92, p =0.026). At 5-year follow-up,  a significant reduction in left ventricular end-systolic volume was  observed in patients with residual MR ≤ 1+. Conclusions – At 5-year follow no significant differences in survival emerged in patients with severe  LV dysfunction undergoing MitraClip therapy regardless residual MR. Nevertheless residual MR > 1+ emerged as an indipendent predictor of re-hospitalization.

Sign in / Sign up

Export Citation Format

Share Document